News for Repligen Corporation (RGEN)

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today an

Repligen Corporation (RGEN) to participate in two major investor conferences in May 2025. Chief Financial Officer Jason K. Garland to represent Repligen

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a \

Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical […]

We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we are going to take a look at where Repligen Corporation (NASDAQ:RGEN) stands...

We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we are going to take a look at where Repligen Corporation (NASDAQ:RGEN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment to highlight the top-performing stocks since the […]

Repligen Corporation reports 11% organic growth in Q1 2025, driven by proteins and strategic initiatives.

Repligen Corporation (NASDAQ:RGEN) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ETCompany ParticipantsJacob Johnson - VP, IROlivier Loeillot -...

Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year

Repligen (RGEN) sees Q1 2025 revenue climb 10% year-over-year to $169 million, with 14% organic non-COVID growth. Adjusted operating income jumps 72

We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management.

Joel Ramin founded 12 West Capital Management in August 2011, establishing it as a New York-based hedge fund specializing in global investments across equities, equity-related instruments, and credit ...

Repligen’s strong growth and bioprocessing expansion position it for success. Find out why RGEN stock is a Buy, with a $175 target and 12% growth in FY25.

908 Devices (MASS) stock soars 71% premarket as Repligen (RGEN) announces $70M acquisition of its bioprocessing analytics portfolio. Read more here.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarte

**media[556718]**

Explore Repligen's Q4 2024 earnings insights, highlighting strong non-COVID growth, standout CDMO performance, innovative product launches, and optimistic...

Repligen (RGEN) delivered earnings and revenue surprises of 7.32% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[545491]**